Promore Pharma Granted a Patent by USPTO for PXL01
IndraStra Open Journal Systems
IndraStra Global

Promore Pharma Granted a Patent by USPTO for PXL01

Promore Pharma Granted a Patent by USPTO for PXL01
On November 12, 2019, the Swedish biopharmaceutical developer of therapeutic peptides — Promore Pharma AB — today announced that its subsidiary Pergamum AB was granted a patent in the US for the pharmaceutical formulation of the product candidate PXL01.

Pergamum AB (Promore Pharma’s subsidiary) owns the intellectual property rights of PXL01, which initially is being developed to prevent post-surgical adhesions after tendon repair surgery. The U.S. Patent Office (USPTO) issued a Notice of Allowance in June 2019 and the patent, which protects the formulation of PXL01 in combination with high molecular weight hyaluronic acid, is today formally granted (US 1 047 1129). The patent is valid at least until January 2030.

“This is an important step in our strategic work to create extensive intellectual property protection for our innovative candidate drug to prevent post-surgical adhesions,” said Jonas Ekblom, President and CEO of Promore Pharma. “In this work, it is of utmost importance to have strong patent protection on the world’s largest pharmaceutical market”, he continued.

The development of PXL01 is initially aiming at preventing postsurgical adhesions after tendon repair surgery in the hand. Post-surgical adhesions constitute a substantial clinical problem after most surgical procedures, and particularly in conjunction with hand surgery. Flexor tendon injury and repair result in adhesion formation around the tendon, which restricts the gliding function of the tendon, leading to decreased digit mobility and impaired recovery of normal hand function. Serious tendon injuries affect more than one million persons per year in the traditional pharmaceutical markets, of which around 30% in the hand. A large share of the patients affected by serious tendon injuries never recovers full mobility. Permanent limitation in mobility is particularly common after injuries in the tendons of the hand, where up to 50% of patients never recover full flexibility and strength in the hand.

NOTE: The company is preparing for a clinical Phase III study in the EU and India. The trial is planned as a randomized, double-blinded study including approximately 600 patients with flexor tendon injuries in the hand where a single administration event of PXL01 at two different doses will be compared with placebo.